SCHEDULE 13G/A 0002092021 XXXXXXXX LIVE 1 Common Stock, $0.00001 par value per share 09/30/2025 0001501989 CytomX Therapeutics, Inc. 23284F105 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 Rule 13d-1(c) Seven Fleet Master Fund LP b DE 0 48898 0 48898 48898 0.02 PN Note to Rows 6, 8 and 9: All such shares are held of record by Seven Fleet Master Fund (as defined in Item 2(a) below). Seven Fleet Management, as the investment manager of Seven Fleet Master Fund, may be deemed to beneficially own the shares of Common Stock held directly by Seven Fleet Master Fund. Seven Fleet Management GP, as the general partner of Seven Fleet Management, may be deemed to beneficially own the shares of Common Stock beneficially owned by Seven Fleet Management. The Reporting Individual, as the managing member of Seven Fleet Management GP, may be deemed to beneficially own the shares of Common Stock beneficially owned by Seven Fleet Management GP. Note to Row 11: Based on 169,435,395 shares of Common Stock (as defined in Item 2(d) below) outstanding as reported by the Issuer (as defined in Item 1(a) below) in its Quarterly Report on Form 10-Q dated September 30, 2025, and filed with the Securities and Exchange Commission (the "Commission") on November 6, 2025 (the "Quarterly Report"). Seven Fleet Capital Management LP b DE 0 48898 0 48898 48898 0.02 OO Note to Rows 6, 8 and 9: All such shares are held of record by Seven Fleet Master Fund. Seven Fleet Management, as the investment manager of Seven Fleet Master Fund, may be deemed to beneficially own the shares of Common Stock held directly by Seven Fleet Master Fund. Seven Fleet Management GP, as the general partner of Seven Fleet Management, may be deemed to beneficially own the shares of Common Stock beneficially owned by Seven Fleet Management. The Reporting Individual, as the managing member of Seven Fleet Management GP, may be deemed to beneficially own the shares of Common Stock beneficially owned by Seven Fleet Management GP. Note to Row 11: Based on 169,435,395 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025. Seven Fleet Capital Management GP LLC b DE 0 48898 0 48898 48898 0.02 OO Note to Rows 6, 8 and 9: All such shares are held of record by Seven Fleet Master Fund. Seven Fleet Management, as the investment manager of Seven Fleet Master Fund, may be deemed to beneficially own the shares of Common Stock held directly by Seven Fleet Master Fund. Seven Fleet Management GP, as the general partner of Seven Fleet Management, may be deemed to beneficially own the shares of Common Stock beneficially owned by Seven Fleet Management. The Reporting Individual, as the managing member of Seven Fleet Management GP, may be deemed to beneficially own the shares of Common Stock beneficially owned by Seven Fleet Management GP. Note to Row 11: Based on 169,435,395 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025. Brian Liu b X1 0 48898 0 48898 48898 0.02 IN Note to Rows 6, 8 and 9: All such shares are held of record by Seven Fleet Master Fund. Seven Fleet Management, as the investment manager of Seven Fleet Master Fund, may be deemed to beneficially own the shares of Common Stock held directly by Seven Fleet Master Fund. Seven Fleet Management GP, as the general partner of Seven Fleet Management, may be deemed to beneficially own the shares of Common Stock beneficially owned by Seven Fleet Management. The Reporting Individual, as the managing member of Seven Fleet Management GP, may be deemed to beneficially own the shares of Common Stock beneficially owned by Seven Fleet Management GP. Note to Row 11: Based on 169,435,395 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025. CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080 This joint statement on Schedule 13G is being filed by Seven Fleet Master Fund LP ("Seven Fleet Master Fund"), Seven Fleet Capital Management LP ("Seven Fleet Management"), Seven Fleet Capital Management GP LLC ("Seven Fleet Management GP" and collectively, the "Reporting Entities") and Brian Liu (the "Reporting Individual"). The Reporting Entities and the Reporting Individual are collectively referred to as the "Reporting Persons." The address of the principal business office of each Reporting Person is 960 San Clemente Way, Mountain View CA 94043. Seven Fleet Master Fund is a limited partnership organized under the laws of the Cayman Islands. Seven Fleet Management is a limited partnership organized under the laws of the State of Delaware. Seven Fleet Management GP is a limited liability company organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America. Y See Row 9 of the cover page for each Reporting Person. Seven Fleet Master Fund is the record owner of 48,898 shares of Common Stock. Seven Fleet Management, as the investment manager of Seven Fleet Master Fund, may be deemed to beneficially own the shares of Common Stock held directly by Seven Fleet Master Fund. Seven Fleet Management GP, as the general partner of Seven Fleet Management, may be deemed to beneficially own the shares of Common Stock beneficially owned by Seven Fleet Management. The Reporting Individual, as the managing member of Seven Fleet Management GP, may be deemed to beneficially own the shares of Common Stock beneficially owned by Seven Fleet Management GP. Seven Fleet Management and Longitude Capital Management Co. LLC (together with its affiliates, Longitude) have instituted policies and procedures that may affect the acquisition, holding and disposition of securities held by Seven Fleet Management and its affiliates. As a result of such policies and procedures, the Reporting Persons and Longitude may be deemed to be members of a group within the meaning of within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934 (the Exchange Act). As of the date hereof, based on information provided by or behalf of Longitude, Longitude may be deemed to be the beneficial owner of 11,538,461 shares of Common Stock, constituting 6.8% of the number of shares of Common Stock outstanding (based on 169,435,395 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025). Notwithstanding such policies and procedures, the Reporting Persons expressly disclaim such group membership and beneficial ownership over any Common Stock that they may be deemed to beneficially own by reason of such policies and procedures. This Schedule 13G shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 of the Exchange Act or for any other purpose. See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.* *Except to the extent of his, hers, or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record. Sole power to vote or to direct the vote See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.* Shared power to vote or to direct the vote See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.* Sole power to dispose or to direct the disposition of See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.* Shared power to dispose or to direct the disposition of See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.* Y Y Y N See Exhibit 1. Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Seven Fleet Master Fund LP /s/ Dr. Brian Liu 11/14/2025 Seven Fleet Capital Management LP /s/ Dr. Brian Liu 11/14/2025 Seven Fleet Capital Management GP LLC /s/ Dr. Brian Liu 11/14/2025 Brian Liu /s/ Dr. Brian Liu 11/14/2025